Aardvark Therapeutics securities class action

MiNK Therapeutics, a clinical-stage biopharmaceutical company, is facing a securities class action lawsuit filed by shareholder rights law firm Robbins LLP. The lawsuit alleges that Aardvark misled investors regarding the viability and efficacy of its lead drug candidate ARD-101, which is being developed to treat hyperphagia in Prader-Willi Syndrome. The complaint claims that the company failed to disclose that ARD-101 was less safe than represented, leading to overstated clinical, regulatory, and commercial prospects. The class period covers investors who purchased Aardvark securities from its February 13, 2025 IPO through May 14, 2026. The stock dropped significantly following two adverse events: on February 27, 2026, Aardvark voluntarily paused its Phase 3 HERO trial due to reversible cardiac observations, causing a 56.2% stock decline; and on May 14, 2026, the United States — Food and Drug Administration placed a full clinical hold on ARD-101's investigational new drug application, leading to a further 32.1% decline. Investors have until October 13, 2026, to seek lead plaintiff status.